Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

BACKGROUND: (131)I-metaiodobenzylguanidine (MIBG) is an active radiopharmaceutical in neuroblastoma. A previous study demonstrated that MIBG could be combined with vincristine and prolonged irinotecan, although 25% of first courses had grade 3 diarrhoea. The current phase I/II study evaluated MIBG w...

Descripción completa

Detalles Bibliográficos
Autores principales: DuBois, S G, Allen, S, Bent, M, Hilton, J F, Hollinger, F, Hawkins, R, Courtier, J, Mosse, Y P, Matthay, K K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333502/
https://www.ncbi.nlm.nih.gov/pubmed/25602966
http://dx.doi.org/10.1038/bjc.2015.12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333502/
https://www.ncbi.nlm.nih.gov/pubmed/25602966
http://dx.doi.org/10.1038/bjc.2015.12

Ejemplares similares